Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients. (11th January 2016)
- Record Type:
- Journal Article
- Title:
- Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients. (11th January 2016)
- Main Title:
- Advantage of tacrolimus/mycophenolate mofetil regimen for cytotoxic T cell-mediated defence and its inhibition by additive steroid administration in high-risk liver transplant recipients
- Authors:
- Uemoto, S
Ozawa, K
Kaido, T
Mori, A
Fujimoto, Y - Abstract:
- Summary: Our previous work revealed that the recipients with the highest pre-existing numbers of CD8 + effector T cells (TE ) [hyperparathyroidism (HPT)E recipients] occupied approximately 30% of adult transplant recipients performed in our hospital. HPTE recipients demonstrated very poor clinical outcome compared with the remaining 70% of recipients with the lowest pre-existing TE (LPTE recipient). This study aimed to clarify the best combined immunosuppressive regimen related to function of cytotoxic T lymphocytes (CTLs) for HPTE recipients. Eighty-one HPTE recipients were classified into three types, according to the immunosuppressive regimens: type 1, tacrolimus (Tac)/glucocorticoid (GC); type 2, Tac/mycophenolate mofetil (MMF)/GC; and type 3, Tac/MMF. Frequencies of severe infection, rejection and hospital death were the highest in types 1 and 2, whereas the lowest occurred in type 3. The survival rate in type 3 was the highest (100%) during follow-up until post-operative day 2000. Regarding the immunological mechanism, in type 1 TE perforin and interferon (IFN)-γ were generated through the self-renewal of CD8 + central memory T cells (TCM ), but decreased in the early post-transplant period due to marked down-regulation of interleukin (IL)-12 receptor beta-1 of TCM. In type 2, the self-renewal TCM did not develop, and the effector function could not be increased. In type 3, in contrast, the effectors and cytotoxicity were correlated inversely with IL-12Rβ1 + TCMSummary: Our previous work revealed that the recipients with the highest pre-existing numbers of CD8 + effector T cells (TE ) [hyperparathyroidism (HPT)E recipients] occupied approximately 30% of adult transplant recipients performed in our hospital. HPTE recipients demonstrated very poor clinical outcome compared with the remaining 70% of recipients with the lowest pre-existing TE (LPTE recipient). This study aimed to clarify the best combined immunosuppressive regimen related to function of cytotoxic T lymphocytes (CTLs) for HPTE recipients. Eighty-one HPTE recipients were classified into three types, according to the immunosuppressive regimens: type 1, tacrolimus (Tac)/glucocorticoid (GC); type 2, Tac/mycophenolate mofetil (MMF)/GC; and type 3, Tac/MMF. Frequencies of severe infection, rejection and hospital death were the highest in types 1 and 2, whereas the lowest occurred in type 3. The survival rate in type 3 was the highest (100%) during follow-up until post-operative day 2000. Regarding the immunological mechanism, in type 1 TE perforin and interferon (IFN)-γ were generated through the self-renewal of CD8 + central memory T cells (TCM ), but decreased in the early post-transplant period due to marked down-regulation of interleukin (IL)-12 receptor beta-1 of TCM. In type 2, the self-renewal TCM did not develop, and the effector function could not be increased. In type 3, in contrast, the effectors and cytotoxicity were correlated inversely with IL-12Rβ1 + TCM levels, and increased at the highest level around the pre-transplant levels of IL-12Rβ1 + TCM . However, the immunological advantage of Tac/MMF therapy was inhibited strongly by additive steroid administration. … (more)
- Is Part Of:
- Clinical and experimental immunology. Volume 184:Number 1(2016:Apr.)
- Journal:
- Clinical and experimental immunology
- Issue:
- Volume 184:Number 1(2016:Apr.)
- Issue Display:
- Volume 184, Issue 1 (2016)
- Year:
- 2016
- Volume:
- 184
- Issue:
- 1
- Issue Sort Value:
- 2016-0184-0001-0000
- Page Start:
- 126
- Page End:
- 136
- Publication Date:
- 2016-01-11
- Subjects:
- central memory T cells -- highest pre-existing effector T cells -- IL-12Rβ1+ cells -- immunosuppressive regimen -- living donor liver transplantation
Immunopathology -- Periodicals
616.079 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2249 ↗
https://academic.oup.com/cei ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cei.12740 ↗
- Languages:
- English
- ISSNs:
- 0009-9104
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.251000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 20719.xml